These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 15963358)
1. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope. Schreurs MW; Kueter EW; Scholten KB; Lemonnier FA; Meijer CJ; Hooijberg E Vaccine; 2005 Jul; 23(31):4005-10. PubMed ID: 15963358 [TBL] [Abstract][Full Text] [Related]
2. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538 [TBL] [Abstract][Full Text] [Related]
3. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Doan T; Chambers M; Street M; Fernando GJ; Herd K; Lambert P; Tindle R Virology; 1998 May; 244(2):352-64. PubMed ID: 9601506 [TBL] [Abstract][Full Text] [Related]
4. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11. Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861 [TBL] [Abstract][Full Text] [Related]
5. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326 [TBL] [Abstract][Full Text] [Related]
6. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18. Castellanos MR; Hayes RL; Maiman MA Gynecol Oncol; 2001 Jul; 82(1):77-83. PubMed ID: 11426965 [TBL] [Abstract][Full Text] [Related]
7. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545 [TBL] [Abstract][Full Text] [Related]
8. [Immunogenicity of mutant and wild HPV16 DNA vaccines]. Zuo YG; Wang JB; Jin HZ; Yue-hua L Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Oct; 26(5):554-7. PubMed ID: 15562771 [TBL] [Abstract][Full Text] [Related]
9. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Huarte E; Sarobe P; Lu J; Casares N; Lasarte JJ; Dotor J; Ruiz M; Prieto J; Celis E; Borrás-Cuesta F Clin Cancer Res; 2002 Jul; 8(7):2336-44. PubMed ID: 12114438 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265 [TBL] [Abstract][Full Text] [Related]
11. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Youde SJ; Dunbar PR; Evans EM; Fiander AN; Borysiewicz LK; Cerundolo V; Man S Cancer Res; 2000 Jan; 60(2):365-71. PubMed ID: 10667589 [TBL] [Abstract][Full Text] [Related]
12. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Street MD; Doan T; Herd KA; Tindle RW Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516 [TBL] [Abstract][Full Text] [Related]
13. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645 [TBL] [Abstract][Full Text] [Related]
14. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648 [TBL] [Abstract][Full Text] [Related]
15. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Michel N; Osen W; Gissmann L; Schumacher TN; Zentgraf H; Müller M Virology; 2002 Mar; 294(1):47-59. PubMed ID: 11886264 [TBL] [Abstract][Full Text] [Related]
16. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers. Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206 [TBL] [Abstract][Full Text] [Related]
18. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination. Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer. Xu DH; Zhou CH; Xia YP; Qiu ZY; Wu YZ; Jia ZC; Zhou W Acta Pharmacol Sin; 2007 May; 28(5):695-702. PubMed ID: 17439726 [TBL] [Abstract][Full Text] [Related]
20. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. Jochmus I; Osen W; Altmann A; Buck G; Hofmann B; Schneider A; Gissmann L; Rammensee HG J Gen Virol; 1997 Jul; 78 ( Pt 7)():1689-95. PubMed ID: 9225046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]